Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alleyba says.....................
............that $4.1000,000 is the tip of the iceberg as SCRC begins to expand into other states. We have not even seen the results yet for PIMD as they ramp up and same as to RX numbers. This is a hidden gem imo. Once we get the Rapi meds order shipped and I believe it will be shipped I think there will be many orders forthcoming after that. I think we just need some new blood into the stock. There are those on this board that are sour on SCRC so they should sell. Even if one assumes a 15-20% profit on the compounding and a monthly run rate is factored in how can this stock lose with all of its revenue streams producing once they are geared up?
Alleyba says...............................
................that things take time. He has owned pharmaceutical stocks that do business with China. Regulatory laws in China take time but I will guarantee we will eventually ship them in my opinion
Alleyba says...................
...............Darth just like I never got answers I am guessing neither will you. I hear big things are coming for IFUS and all are positive. I do not find any negative comments or articles on MW when I google him nor is there anyhting negative on company
Alleyba says...............
...............that I have no idea what the motive was behind the post. I do not think I had posted in days. My position is that anyone who has put up their money to back this company because they believe in the company certainly has a right to potentially make money as that person has taken the risk to do so. I am a firm believer that this month's number's as pointed out by CHP was on pace to surpass $3,000,000 and I hope it dos happen and then wait for this stock to go to the moon when compounding is expanded into other states............so you can all drink, eat and be merry as the only work I have to do come Monday is on my full time job.
Alleya says.........................
..............please show him evidence that MW has judgements against him and/or the company, that the revenue numbers are what you claim they are......show me some semblance of truth that backs up what you say or claim
Alleyba says.........
...........if judgments and bankruptcies exist against Mw then they are a matter of public record. Can you please produce them as well as well as the list of companies they were thrown out of? Thank you
Alleyba says...........
........Can you tell me exactly what this case is about and the history behind it....so I can make my own determination as to who will or will not prevail?
Alleyba says.............................
.............that he agrees with Matin's posts today. How is this for a scenario. Mr. X works as a sales person for Mr. Z. mr. X then sells product gets paid by a check. Mr. X then deposits the check and endorses it to himself and deposits it in his bank account therefore defrauding and stealing from Mr. Z. Does that not constitute a crime or felony? Isn's X not stealing from Z? Bingo
Alleyba says...................
.............that he believes company on the verge of making a big splash in the market. No pun intended but this is my bale outer. I think we can go to a dime or higher once MW wins his legal battles which I hear is just a matter of time from reading all the posts on this board.
google it
Alleyba says..............
...........that Guts is right. It is a pyramid that keeps increasing sales each month. This company is poised to accomplish increasing revenues each month and is, as per prior releases moving into other states. I suggested that they explore compounding of vetinary drugs and wholesaling drugs to veterinarians. Who knows maybe someone may listen........but the compounding and RX revenues home run imo. Let us hope Bob keeps up the good work.
Alleyba says.............................
..........in a commision business it is not uncommon for commisions earned in June to be paid on the last day of July and that any default in the interim to be deducted from the sales person.
I used to have a problem when it would seemingly appear that a commission which could have been earned on the last day or last week of month would be pushed into following month so I would be out of pocket another 30 days. Do not know how they are paid here, this is just general talk.
I personally like the revenue streams that Bob has going here and he really hit a bonanza when he switched gears into the compounding. When you look at the numbers imo they seem very impressive. We need to get the word out on the street about this stock and get some fresh blood in here
Alleyba says that.....................
.............in his opinion the news release today validates what the CEO said on the legends radio interview ......namely any notes are in the hands of his wife and perhaps himself (I do not remember but it was at the end of the call). No convertible outstanding debt bodes well for shareholders. I am hoping for very strong numbers when they are announced and it will not be long before those on wall street see this stock as a hidden gem
Alleyba says..................
.........although you may think it is forward looking, it appears these items he outlined are coming to fruition. If, as you allege, Joe Z got 6,000,0000 shares, in my opinion, and I could be naive, he is holding most of these shares and I think he is working very hard to promote this company and I give him a lot of credit.....but you can disagree if you would like because you are entitled to your opinion as I am to mine
Alleyba says....................
..........that he received a copy of an e-mail forwarded to him from a shareholder who actually visited the plant of PIMD in Doral, Florida and stated in the e-mail they were so swamped with orders that they are thinking of putting on a double shift. This tells me that compounding revenues for this month could possibly exceed $2 million; moreover, he said in the e-mail that he was advised that more sales people were hired and that they are expanding their licenses to several more states. This bodes very well for shareholders and Alleyba is very excited about what he read and if
i did not receive copy of e-mail on work computer could have cut and pasted it for board but I am blocked from numerous sites. I think Bob deserves pat on back for his vision in moving to the compound pharmacy arena
Alleyba says.....................
..................that the interview in my opinion on radio as per the stock legend link was an awesome interview in that Alleyba thought CEO was quite candid and clearly laid out his game plan for the company and answered all questions asked of him clearly and concisely. He pointed to the numerous revenue streams that are being generated and said company will look to expand into the south american market. His points on China were very true and he pointed out why China would desire our product.
He made a point at end of interview to say that there is no new toxic paper out there and he does not intend to take on any more such paper. For those who believe in the company and wish to invest their money and risk it why should they not be rewarded with RESTRICTED stock at a discount, after all they are taking the risk with their money? As I have said several times and mentioned by CEO in interview, the company switched gears midstream to delve into the compounding niche which imo was a bold move which should pay dividends to all shareholders in the future.
Alleyba says..........................
............that he agrees with Martin that the chart looks fantastic and it is a matter of time before we hit .20. I added to my position yesterday at .13 and see this scrc ready to break out
Alleyba says........................
..........that in his opinion CEO made the correct and bold move by restructuring the crux of this company by moving into the compounding drug niche. It would not surprise me if CEO were looking for other companies similar to Main Avenue to acquire..........and let us not forget our other revenue streams. I would agree with my fellow longs that we can easily be between $1.50-$2 given the numbers company is doing on compounding alone and then factor in the other revenue streams. This is a long term hold and an excellent buy at this price
Alleyba says...............
...............that link posted by Fudge just emphasizes the amount of revenue streams this company has; moreover, I would not be surprised that Martin'S comments are accurate based on company history which is to increase numbers substantially month to month..so if they almost did $1,000,000 last month on compounding I would expect, imo, a 25% increase or maybe more.
In addition think this will be a good summer for this stock as I am looking forward to PIMD ramping up more acquisition of compounding companies, more licensing in different states and whatever good and positive things Bob has in the works.
Alleyba says........
that the "pipe stock" you refer to may be going toward payment of toxic debt, acqusition of another compounding company, and/or the build up of inventory. How else could they rasie the money other than this? Are yoyu suggesting they make more deals for toxic stock?
We may have differnces of opinion but I think Bob is really trying to build a real company here.
Alleyba says....................
...........this is an interesting article on compounding....
By Jaimy Lee
Posted: January 19, 2013 - 12:01 am ET
Tags: Acquisitions, Deals, New England Compounding Center, Pharmaceuticals, Suppliers, The Week in Healthcare, U.S. Food and Drug Administration (FDA), Walgreen
Ongoing shortages of sterile injectable drugs have triggered a wave of investment in new and existing compounding pharmacies, which so far, at least, hasn't alleviated the shortages.
A combination of high margins, persistent drug shortages and cash-strapped hospitals unwilling to invest in their own sterile pharmacy facilities has ignited interest from a number of investors. They include private equity firms, drug and device manufacturers and healthcare management firms.
“This whole industry popped up,” said Lou Diorio, a principal with LDT Health Solutions, a pharmacy consulting firm. “It's gained such momentum over the last three or four years.”
Advertisement | View Media Kit
Compounding began at local pharmacies, which traditionally formulated sterile and non-sterile prescriptions for individual patients. However, the rising number of drug shortages as well as the introduction a decade ago of new regulations that established stricter rules for the production of sterile drugs have made hospitals increasingly reliant on obtaining sterile injectable drugs from compounding pharmacies, some of which are operating more like small drug manufacturing plants.
Little attention had been paid to this under-regulated and largely fragmented segment of the drug market until a contaminated batch of steroid injections compounded by the New England Compounding Center last year led to the deaths of 44 people and sickened an additional 678 patients. The Food and Drug Administration has, for the most part, left oversight of the industry to the states.
The scale of NECC's reach—the company eventually recalled more than 2,000 products after distributing 17,000 vials of the tainted steroid injections to 23 states—pushed federal regulators and lawmakers to consider new rules for compounding pharmacies that operate more like drug manufacturers. New industry regulations are likely, but are still some time away.
Pharmacists say that whatever the scope of the new regulations, compounders will continue to play a crucial role in the supply chain and that should drive more investment in the sector.
“In health systems, with so much uncertainty, with healthcare changing on a daily basis, a hospital might not want to give a couple million dollars to its pharmacy to get it up to snuff,” said Erin Fox, director of the drug information service at the University of Utah Hospitals and Clinics. “It's easier to spend a little extra to get the drugs from someone else.”
Deals, partnerships and investments in the sector have accelerated in recent years. Walgreen Co. acquired a compounder owned by Omnicare in 2010. Arise Healthcare, which owns surgery centers and other healthcare facilities, opened the Texas Compounding Pharmacy in 2009. The compounder is now licensed in 15 states.
Private equity firms also have been active in the space. Last year, Baxter International considered purchasing Pharmedium, a national compounding pharmacy owned by Oak Investment Partners, Baird Capital Partners and Baird Venture Partners, but it backed away because of the possibility of new industry regulations, according to media reports. A Baxter spokeswoman said the company does not comment on rumors, and Pharmedium did not return calls for comment.
In December, two more deals were announced. Arseus, a Rotterdam-based medical supplier, said it would buy B&B Pharmaceuticals, an Aurora, Colo.-based supplier of controlled substances and raw materials used in compounding. Pharmagen, a publicly traded distributor of specialty and scarce drugs, spent $1.1. million to acquire Bryce Rx Laboratories, a Stamford, Conn.-based compounder.
Pharmagen, formerly Sunpeaks Ventures, aims to serve as the primary backup supplier of drugs in short supply to U.S. hospitals, said Mackie Barch, Pharmagen president and CEO. It bills itself as the first integrated company that is working actively on the sterile drug shortage.
The number of new drug shortages has nearly tripled in the past six years, jumping from 70 in 2006 to 204 in 2012. There were 299 active shortages in the fourth quarter of 2012, compared to 188 in the same quarter in 2010.
“I don't see any near-term resolution” to drug shortages, Barch said. “I wouldn't be in this business if we saw it going away in a year or two.”
Barch is the former managing director of HealthRite Pharmaceuticals, a now-closed pharmacy that was cited in a congressional investigation into secondary drug distributors that were accused of selling drugs in short supply at marked-up prices.
The link highlights how some companies have emerged as players in the secondary drug distribution and pharmacy compounding markets. NECC, along with selling compounded drugs, had also been marketing drugs in short supply to providers before the meningitis outbreak.
A report published by research firm IBIS World cited drug shortages, the public's increased awareness of compounding pharmacies and an aging population as factors in the industry's growth during the past five years. A separate report released last year by the private equity firm Bain & Co. identified pharmaceutical compounding as a consolidation opportunity that could yield “outsized profit margins.”
Diorio of LDT Health Solutions said another factor driving provider reliance on compounders is the number of hospitals that choose not to build their own sterile facilities. About 70% of hospitals surveyed in 2011 by the American Society of Health-System Pharmacists said they “partially or completely outsource some drug preparation activities.”
“You're always going to have the 50-bed hospitals that are not going to be able to make that investment,” Diorio said. “There's always going to be a need for some compounding.”
Alleyba says..............
............to say there is not a risk is a statement I am surprised that anyone would make. Of course there is a risk! How could there not be. Does anyone have a crystal ball that will guarantee a profit or break even after shares unlock? I hardly think so; moreover, I think your statements about Joe Z are misplaced because no one wants this company to succeed more than him. I think it was a coincidence that the moneyrunners ran the stock up that day and I paid in the .80's or .90's that day and was caught just like everyone else or I should say a lot of shareholders. I know you would not beleive it, but Joe Z bought that day and was caught in the MR web as well
Alleyba says................
..........that when the compounding emphasis came into play that appears to be when the .052 stock was offered coupled with the money needed to buy out toxic notes. People who RISKED THEIR money betting on this company deserve to get what they get in my opinion, because no one here is going to be chsaritable and reimburse them should they lose.
I beleive the raising of that money, in my opinion, may be for the acquisition and expansion of this lucrative compounding industry down the road and/or even now as I beleive Bob has righted ship and has on a clear course. I beleive the run rates will improve and I cannot wait to see the numbers as they come out going forward. The company, if this were a horse race, seems to be sitting the perfect trip
Alleyba says.....................
............that he ciuld not be more pleased with all the positive news that has been released by the compounding insofar as the growth of the compounding business. As far as the .053 stock is concerned those people put up THEIR OWN MONEY and tool the RISK. Are members of the board prepared to repay them if they lose their money on stock that I believe is restricted? Hardly NOT. They TOOK THE RISK!!.
Very pleased with the increase in compunding revenues. Great stategy and great insight by CEO to shift gears to this niche area. In my opinion we should go route of trying to acquire compounding companies outright so we can make all the revenues. Perhaps this is the long range plan.
All I am seeing is increase in revenues in compounding, TM. and we have yet to see PIMD take off; moreover, once the company announces the delivery of the order to HONG KONG I can give you all 200,000 reasons to not knock the company
Alleyba says...............
.................that he is in agreement with Martin. Had loyal shareholders not risked THEIR money, SCRC would not have been able to switch gears and concentrate on the compounding of drugs. When reading the press release today I had almost a million reasons to smile. In my opinion when the Rapimeds is sent to Hong Kong I will have another 200,000 reasons to smile.
As noted in my prior posts in articles I pasted and copied from the Boston Globe this compounding is a homerun and a niche
Alleyba says...............
...........that he agrees with Martin. The compounding industry is highly profitable and there is a big profit margin. I beleive as I am wrting this SCRC is stil tabulating last month revenues from the compounding business and, when released, I am of the opinion there will be a significant percentage increase over last month's numbers.I also beleive the revenues to SCRC are much higher than what has been previously posted on the board by some other individusls.
The revenue stream in Tn. is improving in my opinion and with the addition of additional states as posted on the board that we are now licensed in this compound niche is bolstering the companies's revenues.
And lets see.........oh yeah forgot the Rapimeds order. That is still pending also which, when filled by SCRC will bring in more money. Should be an interesting month for the company in my opinion
Alleyba says..................
........that here is more proof that compounding pharmacies becoming more and more of a niche market. Following is article cut and pasted through Boston Globe published in 2014. Stay the course BOB
Among the many surprises that have emerged since a Framingham pharmacy was implicated in a national fungal meningitis outbreak is this one: Hundreds of US hospitals, including most of those in Massachusetts, bought medications from the lightly regulated New England Compounding Center.
Unlike major drug manufacturers, the specialty pharmacy was not regularly inspected or monitored by the Food and Drug Administration, yet prestigious hospitals from Massachusetts General to Yale-New Haven were among its customers, according to a list posted online by the FDA.
Hospitals and pharmacists say companies such as New England Compounding play a critical role in supplying scarce drugs, specialized medications, and individually packaged doses. But over the years, some companies have grown so large that they quietly crossed a line, acting more like drug manufacturers than pharmacies that prepare drugs for individual patients.
Related
Globe coverage of the outbreak
Covering the meningitis outbreak
“We do think we need to clarify some of the regulations and who is doing the regulation,” said Dr. Elizabeth Mort, interim senior vice president of quality and safety at Massachusetts General Hospital. “We want to be part of that conversation, because we’re at the delivery end. We want to make sure we have continuous, uninterrupted, high-quality drugs delivered to our patients.”
More stringent standards for preparing sterile drugs, which can include everything from injections to eyedrops, helped build demand for compounding pharmacies that specialized in such drugs. Problems at big drug makers have caused shortages of many of the injectable medications hospitals commonly need. And manufacturers do not always make drugs in the individual doses that hospitals prefer to use to reduce the risk of medication errors and contamination.
As a result, hospital pharmacies prepare many of their own drugs, but they also outsource some of the work to pharmacy companies that are licensed and regulated as manufacturers by the FDA, a fact underscored by the flurry of activity to come up with alternate suppliers after Ameridose, the much larger sister company of New England Compounding, recalled all its products this week.
Some hospitals also turn to compounding pharmacies that are not licensed manufacturers for a small portion of their medications.
The reasons include textbook cases of what compounding is: making specialized medicines fine-tuned to the needs of an individual, such as an intravenous medication that could ease the pain of a terminally ill patient. For example, Mass. General would place individual orders with New England Compounding for patients who needed high doses of pain medication, Mort said.
But among the products New England Compounding shipped since May 21 were many that were delivered to hospitals in quantities of dozens to hundreds, according to company records released by the FDA.
At Baystate Medical Center, which regularly ordered injectable drugs in quantities of several dozen at a time, chief pharmacy officer Gary Kerr said it placed orders and would receive drugs the next day. The company, he said, had an uncanny ability to get scarce medications.
“It is difficult for us to understand, us being pharmacy leaders, how they were able to procure particular drugs that I was not able to procure,” Kerr said. “But the fact remained they did have things I could not buy.”
A 2011 survey by the American Society of Health-System Pharmacists found that 71 percent of the more than 500 hospitals that responded said they outsourced some or all of their drug preparation activities, although it did not ask whether they used compounding pharmacies or manufacturers.
Several local hospitals reported that they relied on compounding pharmacies for only a small number of drugs.
Brigham and Women’s Hospital outsources 20 percent of its sterile drugs. Of those, less than 2 percent were outsourced to New England Compounding; the rest were bought from Ameridose and CAPS, another company licensed as a manufacturer.
Tufts Medical Center said that about 1 percent of 2 million doses of medication administered annually are procured from a compounding pharmacy.
Many hospitals turn to such pharmacies because they can prepare doses of a drug that can sit on the shelf longer. Compounding pharmacies are more likely to invest in testing intended to ensure the potency and sterility of a drug over a long time span.
Tufts and Brigham and Women’s said they both used New England Compounding’s cardioplegic solutions, used in cardiac surgery, because of their longer expiration dates.
A shift in recent years to using drugs in single-dose packaging and with barcodes, both designed to reduce medication errors and contamination, contributed to hospitals’ need to outsource drugs.
Strict guidelines for preparing sterile drugs, written in 2004 by the US Pharmacopeial Convention, a nonprofit that sets requirements for drug compounding, also led hospitals to rely on external companies.
Hospitals also said they use compounding pharmacies to fill drug shortages, which have increased in number and length.
“The irony is you have these people who are subject to far less stringent regulation jumping into the breach and producing . . . an inferior product,” said Frances Miller, a professor at Boston University School of Law, referring to the New England Compounding injectable steroid blamed for the meningitis outbreak.
When hospitals ordered in bulk from New England Compounding, they were not always required to provide individual patient prescriptions. A Mass. General pharmacist said the hospital was told by New England Compounding to order cardioplegia solution and retain the names of individual patients who received the drug.
“We would have them on file, ready at any time to send” to the company or to regulators, said Margaret Clapp, chief pharmacy officer at Mass. General. To avoid patient privacy and confidentiality issues, the information would not be transferred unless it was requested.
Kerr of Baystate said his hospital complied with the requirements set forth by New England Compounding, which did not demand prescriptions for each dose.
“This is where you run into a grey area in the law,” said Bona Benjamin, director of medication use quality improvement at the health system pharmacists group. Pharmacies are allowed, she said, to make a small amount of extra drug in anticipation of patient need, so that there is sufficient drug on hand for patients.
But, she added, “when you get into preparing thousands and thousands of prescriptions in anticipation, then you run into problems with mass production and inadequate quality control. I think it’s here where we need some clarification around where you cross the line between compounding and manufacturing.”
Carolyn Y. Johnson can be reached at cjohnson@globe.com.
© 2014 BOSTON GLOBE M
Alleyba says..............
..........that perhaps the numbers were so high and that is causing the delay in tabulating them (:). SCRC has clearly, to a certain degree, changed direction to a certain degree when the excellent decision was to go the compounding route which is a very niche but important part of the pharaceutical industry.
I am predicting very strong numbers from Main Avenue based on prior posts and the fact that every month when SCRC releases numbers they are always significantly better than the month before
Alleyba says.................
...........that hd thinks it would have to be NJ and TN. and that applications pending in other states. The compounding business is doing very well from what I hear
Alleyba says.............
............that he concurs with Martin and happened to send a friend to the Main Avenue, New Jersey, pharmacy who asked some generic questions regarding the compounding of drugs. He was advised business was booming and I would not be surprosed to see nice revenues coming out of this venture.
Also read article that compunding of drugs saves hospitals thousands of dollars by not having to order drugs in bulk. There is a google article under compunding of drugs and the article was released by the Boston Globe so check it out.
Also the more states we get licensed in, the more compounding revenues we can achieve. I like the direction we seem to be going
Alleyba says.................
.................that he read interesting article published in Boston Globe. Compounding pharmacies becoming niche in pharmacy area.
This tells me that our CEO has a good visionary plan. It is highly lucrative industry.
Alleyba, in his opinion believes SCRC will become more entrenched in acquiring these compounding companies which is pure speculation, but thinks revenue stream in TN. doing well and compounding will have increased sales as referenced in posts posted today. Read article and let us watch SCRC continue to climb.
WALTHAM — Wielding a glass mortar and pestle, pharmacy intern Joanne Lee mixes liquid medication used to treat parasites. It’s grape-flavored, to appeal to a child’s palate. At a nearby work station, a worker clad in gloves, mask, lab coat, boots, and hairnet weighs powder under a protective hood. Other technicians at Johnson Compounding & Wellness Center prepare hormone cream, produce vitamins, and heat a viscous gel to make a customized suppository.
The pristine, brightly lighted laboratory, visible behind a wall of windows at the back of the store, provides a glimpse of a niche area of drug preparation that has been abruptly thrust into the spotlight. A widening outbreak of fungal meningitis linked to steroids made by a Framingham compounding pharmacy has focused scrutiny on the regulation of such businesses. But much about how compounding pharmacies function, and even what compounding really is, has remained obscure.
The New England Compounding Center, the pharmacy implicated in the infections, was apparently preparing drugs for bulk, nationwide distribution, raising questions about why it was not licensed and held to the standards of a manufacturer. But such broad distribution is not what most compounding pharmacies are set up to do. Instead, they predominantly serve a limited geographic region — filling individual prescriptions for patients and often developing specialties based on the needs of their clients, pharmacists say.
Related
Fungal infection strikes 4 in N.H.
Stephen and Diane Bernardi met in pharmacy school and bought Johnson Compounding in 1987. When they took over the brick pharmacy on Main Street, Stephen Bernardi recalled, his parents helped clean it up. It was decidedly conventional then, filling many run-of-the-mill prescriptions, the shelves stocked with cigarettes, perfume, and makeup. But over the years the custom medication business grew, as the proliferation of chain stores meant increased competition for filling standard prescriptions.
“I liked compounding better; people could get the regular stuff anywhere,” said Stephen Bernardi, who began working in a Framingham pharmacy when he was 14 years old.
Today, his pharmacy’s shelves are stocked with herbal teas and natural medicines, and the sound of water burbles in the background, creating a spa-like atmosphere. But behind the counter, it is all business as pharmacists bustle, checking formulations. In a back room, four pharmacy technicians receive 80 to 100 prescriptions a day. They put orders into an organized row of boxes mounted on the wall, and formulations are checked by three people before filling.
Johnson Compounding has two laboratories — one for sterile drug preparation, one for other drugs. Both are protected, separated from the rest of the pharmacy by two sets of doors, air filters, sticky mats, and other measures to prevent contamination.
The sterile room — where injectable drugs or preservative-free eyedrops are made — is restricted to workers who are specifically trained. Pharmacists regularly perform a “fingertip test,” in which they touch their gloved fingertip to a lab dish, then incubate that sample and examine and document whether bacteria or other pathogens are present.
Pharmacies such as these are not preparing and shipping thousands of vials of drugs, but play a crucial role for patients and doctors who need specialty formulations. Compounders make drugs for children who may need a different dose, concoct medications from raw ingredients to leave out substances that could cause an allergic reaction, create doses appropriate for a pet, or prepare treatments not otherwise available.
“Historically, this was a specialized niche, almost a boutique type of pharmacy practice,” said David G. Miller, chief executive of the International Academy of Compounding Pharmacists, a professional association.
As the compounding pharmacy business has grown, Miller said, it has also become more diverse. Some companies focus on one specialty, such as veterinary medicine. About 1 percent to 3 percent of US prescriptions are compounded, Miller said.
The Pharmacy Compounding Accreditation Board conducts an extensive two-day site visit at Johnson Compounding & Wellness Center every three years. The accreditation is voluntary, but it is a stamp of approval intended to confirm that everything is in compliance.
Policies and procedures are reviewed, and testing logs are examined. Certificates showing the potency and sterility of drugs are inspected, and facilities and equipment are scoured. Johnson Compounding sends two drugs each week for potency and sterility testing.
New England Compounding Center did not have such accreditation.
Bernardi said he would favor mandatory accreditation.
Todd Brown, executive director of the Massachusetts Independent Pharmacists Association, said 120 independent pharmacists — essentially mom-and-pop stores — are members, with only three to four dozen doing compounding as a significant portion of their business.
He said that he has not heard concerns from members about the state’s new order, announced Wednesday, requiring all compounders in Massachusetts to sign an affidavit stating that they abide by state regulations prohibiting compounders from mass-producing medications.
Brown said his members are worried the entire field will be tainted by New England Compounding.
“These are pharmacies that go to great lengths to help patients,” Brown said. “So, to see this associated with a compounding pharmacy has a lot of my members upset with this situation.”
Alleyba says..................
.....that he expresses same sentiments as Martin. It was one of 2 things....selling by Ironridge, selling by shareholders not happy with 10-K, but one thing is clear new blood came into the stock so hopefully we have a new base to work from as we move up. In my opinion, the 10-K came out with all the laundry (which we knew what not be great), but yet the stock closed UP for the week. It also helped crystallize that the main revenue stream will be to develop the niche compounding drugs, ramp up Rapi-meds, and to further expand and develop the sale of generic and controlled substance drugs through the entry of additional states. This is not new information I am putting on here....this has been what the longs have been saying all along.
For those of you who were looking for a short term play we have always said this is long term. I HOPE it was Iron Ridge that cleaned itself out.......but now we have new blood in the stock. Some big blocks went at the end of the day
Alleyba says...............
........that he could not be more pleased with the trading of the stock this week. The 10-K comes out, all the news comes out with whatever has transpired and the stock finishes UP for the week. I think, in my opinion, the stock is headed upwards from here and those who did not like the 10-K certainly had their opportunity to get out and sell their shares. I like the niche that is being created in the compounding drug arena. I like the revenue stream that may be in the infancy stage with Rapi-Meds, I like the revenue stream out of TN. with applications pending in other states for generic and controlled substance drugs and i like the way the CEO is tying everything together and I am of the opinion there is good news to come; moreover, if the selling was not done by shareholders that did not like the 10-K one would have to believe it could be the last of the toxic paper or close to it.
What Alleyba sees now is that SCRC is becoming a very real company with revenue streams. Kudos to Bob S and now we should be positioned to not have to make toxic deals moving forward as he has smartly paid off the notes to avoid the toxic paper from hitting.
In my opinion the longs will be rewarded with a nice move in the share price
Finance Home
My Portfolio
Market Data
ALLEYBA SAYS..........................
...........that this news release helped to somewhat clarify the 10-K, in his opinion. With the many streams of revenue which are now starting to flow like a smooth scenic river, I think 2014 will be a good year for the shareholders. As SCRC expands their compounding business per the post last night that showed that compounding on a large scale is similar to a niche product, I think shareholders can feel pretty good, again in my opinion, if we just stay the course. I have always said this is a long term play
ScripsAmerica Files 2013 Annual Report and Management Comments on Revenue Recognition
GlobeNewswire ScripsAmerica, Inc.
7 hours ago
TYSONS CORNER, Va., April 16, 2014 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (SCRC) today announced that the Company has filed its 10-K Annual Report for 2013 with the Securities & Exchange Commission (SEC).
ScripsAmerica's Gross Revenue generated in the year ended December 31, 2013 increased from $5,583,000 in 2012 to $7,335,000 in 2013 as displayed on page 29 of ScripsAmerica's 10-K under the "Products Sold" column in the section titled "Revenues Net." This increase of $1,752,000 represents an increase of 31% for 2013 over 2012.
Due to financial reporting requirements, ScripsAmerica can report only the net profits from its Joint Government contract and pharmaceutical partner and not the top line revenue, which will continue at an accelerated pace for the remainder of 2014.
"In conjunction with the reporting of its financials for last year, management feels it is very important to remind our shareholders that the Company's required accounting method has a significant impact on reportable revenues from our government joint venture and pharmaceutical equity venture, both of which will continue to generate revenue and profits for ScripsAmerica, increasing shareholder value," commented Bob Schneiderman, CEO of ScripsAmerica.
Alleyba says.................
..........the points you raise are duly noted, but here is how I see it.............before Joe Zampetti got involved in SCRC I believe the amount of convertible notes was somewhere between 50 and 60 million shares if converted.
JZ came in and was able to, by his magic cut that number down dramatically to where I am hearing the outstanding unrestricted psper is less than 2,000,000 shares. If these facts are accurate, I would say he has done an outstanding job and the strategy to eliminate convertible notes to the extent possible has been a big win for SCRC. JZ came in and had to work the reality of countless convertible notes and I highly doubt he knew the extent of the paper when he got involved do I am saying give the msn dome slack and let us move forward and wait for some more positive news as I believe the CEO is moving in the right direction. JZ said this was a long term hold snd I believe him.
I know you portrsy the facts as you see them but let us try to work as a team on this board. The TN. and compound numbers do not lie
Alleyba says...............
.........that is what the pleadings say; however when MR was in that day pumping and dumping the stock it would seem to me that Mr. Zampetti, having recently starting to promote the stock would have had restricted stock, and therefore, he would not have been able to sell any of it at that time, in my opinion.
So let me ask you a few questions since you are so familiar with the filings and have a pretty good handle on SCRC.........(1) how would you go about or what would yuor strategy be in helping SCRC to establish itself as a player in the area they are in (sector of the market); (2) We all know that SCRC had made some toxic deals with regard to convertible notes, which financing was needed to keep company going. They are now getting rid of those toxic notes. What would you have done if you were in their shoes and how differently would you have done it..........I think those are fair questions.
Alleyba says........................
.............that he respects your opinion but respectfully believes that your theory with regard to Mr. Zampetti is misplaced. I certainly think he has been instrumental in promoting SCRC but I understand that he lost a significant amount of his own money when the money runners came in that day.
Further whatever amount of shares JZ has I think he has worked very hard on behalf of the company. I do not know why it seem like there is a personnel vendetta against him
Alleyba says.............
...........that he believes all shareholders at the time were caught by the money runner group that saw scrc run up for 20+ days and then in concert with the traction scrc was getting had their gtoup pump and dump it. I myself got caught in the euphoria at the time and bought in the .80's or .90's. If you may recall the dumping all started happening 20 minutes before the close and the stock went from a $1 to .49. In my opinion this had nothing to do with JZ, Bob or anyone connected to SCRC unless I csn be shown proof to contrary. This had been previously discussed ad-mauseum
Alleyba says...................
............that 2013 was a matter of survival for SCRC and they needed to do what they had to do to survive and implement their plan. We all knew that JZ said this was a long term play. I think they have overcome 2013 and although in my opinion 2013 results may not look favorable what is going forward counts. The revenue streams they are currently building counts. The elimination of toxic convertible notes counts. Acquisitions count. This company will be in the black and I believe CEO will make those shareholders who were patient money in the long run
Peachman........I am obviously long in the stock thanks to a friend I have in NJ. My question is does the CEO know how to close a deal?